PMID- 18068004
OWN - NLM
STAT- MEDLINE
DCOM- 20080327
LR  - 20161124
IS  - 0188-4409 (Print)
IS  - 0188-4409 (Linking)
VI  - 39
IP  - 1
DP  - 2008 Jan
TI  - Mycophenolate mofetil in low doses stabilizes and improves antineutrophil 
      cytoplasmic antibody-associated vasculitis and lupus nephritis.
PG  - 115-9
AB  - BACKGROUND: Clinical experience with mycophenolate mofetil (MMF) in 
      glomerulonephritis still remains limited. METHODS: In order to assess the 
      experience of one center with the efficacy and tolerability of MMF in patients 
      with glomerulonephritis, we performed a retrospective 6-year analysis of 68 
      patients treated by MMF for glomerular disease, mainly anti-neutrophil 
      cytoplasmic antibody-associated vasculitis (AAV: n=34) and systemic lupus 
      erythematosus and lupus nephritis (SLE: n=24). Indications were maintenance 
      treatment in 40% of patients, induction treatment in patients not tolerating 
      cyclophosphamide in 27%, and disease relapse in 33%. Mean treatment duration was 
      11.5 months. RESULTS: Efficacy endpoints were serum creatinine, urinary protein 
      excretion, and steroid dose. In AAV patients, MMF was associated with significant 
      improvement in 18%, partial improvement in 26%, stabilization in 29%, and disease 
      progression in 12%; adverse event dropouts totalled 15%. In SLE, the respective 
      figures were 30, 22, 9, and 22%, with 17% adverse event dropouts. The most 
      frequent side effects were gastrointestinal events (n=7) and infections (n=3). 
      None was life-threatening and there were no deaths. CONCLUSIONS: MMF, in the 
      relatively low doses used, was safe and effective, stabilizing or improving AAV 
      in 73% of patients and SLE in 61%. Further prospective randomized controlled 
      trials with MMF in renal vasculitis and lupus nephritis are clearly warranted.
FAU - Kazderova, Marketa
AU  - Kazderova M
AD  - Department of Nephrology, First Faculty of Medicine and General University 
      Hospital, Charles University, Prague, Czech Republic. mkzderova@centrum.cz
FAU - Jancova, Eva
AU  - Jancova E
FAU - Rysava, Romana
AU  - Rysava R
FAU - Merta, Miroslav
AU  - Merta M
FAU - Tesar, Vladimir
AU  - Tesar V
LA  - eng
PT  - Journal Article
DEP - 20071023
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - 0 (Autoantibodies)
RN  - 0 (Immunosuppressive Agents)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Autoantibodies/immunology
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Lupus Erythematosus, Systemic/*drug therapy/immunology
MH  - Lupus Nephritis/complications/*drug therapy
MH  - Male
MH  - Mycophenolic Acid/adverse effects/*analogs & derivatives/therapeutic use
MH  - Neutrophils/immunology
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vasculitis/*drug therapy/immunology
EDAT- 2007/12/11 09:00
MHDA- 2008/03/28 09:00
CRDT- 2007/12/11 09:00
PHST- 2007/03/12 00:00 [received]
PHST- 2007/07/09 00:00 [accepted]
PHST- 2007/12/11 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/12/11 09:00 [entrez]
AID - S0188-4409(07)00298-6 [pii]
AID - 10.1016/j.arcmed.2007.07.006 [doi]
PST - ppublish
SO  - Arch Med Res. 2008 Jan;39(1):115-9. doi: 10.1016/j.arcmed.2007.07.006. Epub 2007 
      Oct 23.